한빛사논문
- 조회453
Jinho Yoona,b,1, Minkyu Shina,1, Ji-Young Leea, Sang-Nam Leec, Jin-Ha Choid,*, Jeong-Woo Choia,*
aDepartment of Chemical & Biomolecular Engineering, Sogang University, 35 Baekbeom-ro, Mapo-gu, Seoul 04107, Republic of Korea
bDepartment of Chemistry and Chemical Biology, Rutgers, The State University of New Jersey,123 Bevier Road, Piscataway, NJ 08854, USA
cUniance Gene Inc., 1107 Teilhard Hall, 35 Baekbeom-Ro, Mapo-Gu, Seoul 04107, Republic of Korea
dSchool of Chemical Engineering, Jeonbuk National University, 567 Baekje-daero, Deokjin-gu, Jeonju-si, Jeollabuk-do 54896, Republic of Korea
1These authors equally contributed to this work.
*Corresponding authors.
Abstract
RNA interference (RNAi) is being extensively investigated as a potential therapeutic strategy for cancer treatment. However, RNAi-based therapeutics have not yet been used to treat cancer because of their instability and the difficulty of microRNA (miRNA) delivery. Plasmonic nanoparticle-based RNAi nanotherapeutics have been developed for accurate and sensitive diagnosis and a strong therapeutic effect on cancers by leveraging their ease-of-use and specific properties such as photothermal conversion. In this review, recent strategies and advances in plasmonic nanoparticle-based miRNA delivery are briefly presented to facilitate the detection and treatment of several cancers. The challenges and potential opportunities afforded by the RNAi-based theragnosis field are discussed. We expect that the RNAi-integrated plasmonic nanotherapeutics discussed in this review can provide insights for the early diagnosis and effective treatment of cancer.
Keywords : RNA interference (RNAi), microRNA (miRNA), Small interference RNA (siRNA), Plasmonic nanoparticle, Photothermal therapy, Nanobiosensor, Theragnosis
논문정보
- Review Paper
- 2022년 02월 (BRIC 등록일 2022-02-18)
- 국내(교신)+국외 연구진
- 바이오·의료융합 > 바이오센싱 및 나노바이오물질
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
